Could this be a headwind for blood thinner sales that investors missed?
Why specialty drug prices are soaring.
The health insurance mandate means more customers for health insurers, right? It's not that simple.
Shares of JNJ beat a new all-time high.
With robotic surgery, user error is a key variable to consider.
Two different views on the FDA's inquiry into the daVinci surgical robot.
Can generic biosimilars change the pharmaceutical game?
Is this litigation going to be a big deal for Johnson & Johnson?
Has the FDA been reading Citron's reports?
Did Accretive Health deserve today's selloff?
Will new rules around powdered milk products weigh on these consumer nutrition heavyweights?
A quick take on MAKO's earnings release
After an update call from management, there doesn't look like much hope for Affymax investors.
Cost savings could drive Dendreon to profitability.
The worst possible news from a drug company.
Despite predictions of a buyout, this company appears headed for an IPO.
Medicare Advantage rates are set to take a big dive.
Revenue adjusted for foreign exchange isn't revenue, and this company realized it.
Make sure you value cash for what it is....cash.
By better targeting patients, we can cut costs and improve outcomes.